Preclinical proof helps the superior effectiveness of sotagliflozin in attenuating salt-induced kidney harm

Sodium-glucose cotransporter 2 (SGLT2) inhibitors, initially developed to deal with kind 2 diabetes, believe important cardioprotective results. Within the kidney, SGLT2 reabsorbs roughly 97% of filtered glucose within the S1 and S2 segments of the proximal tubule, whereas SGLT1 reabsorbs the rest within the S3 section.

In research in rats, researchers discovered that twin inhibition of SGLT1 and SGLT2 lowered salt-sensitive hypertension and kidney harm extra successfully than SGLT2 inhibition alone. The outcomes shall be introduced at ASN Kidney Week 2025, November 5-9.

Salt-sensitive hypertension – elevated blood strain as a consequence of extreme salt consumption – impacts almost half of of individuals with hypertension and is a significant contributor to kidney illness, cardiovascular issues and the development of kidney failure. When researchers in contrast selective SGLT2 inhibition (by means of therapy with dapagliflozin) with twin SGLT1/2 inhibition (by means of therapy with sotagliflozin) in a well-established rat mannequin of salt-induced hypertension and power kidney illness, they discovered that each medication had profound results in slowing the development of salt-induced hypertension.

In contrast with selective SGLT2 inhibition, twin SGLT1/2 inhibition resulted in a higher discount in imply arterial strain and more practical attenuation of kidney harm, even though it had no impact on blood strain beneath regular saline situations. In comparison with dapagliflozin, sotagliflozin additionally lowered physique weight, elevated urinary sodium and chloride excretion, and almost doubled fractional glucose excretion. Not one of the therapies modified kidney perform. SGLT2 inhibition modulated a number of metabolic pathways in a region-specific method within the kidney, with distinct results on lipid metabolism and inflammatory signaling.

Our examine supplies preclinical proof for expanded exercise of dualSGLT1/2 inhibitors past coronary heart failure and diabetes and expands their potential to deal with hypertension, notably in salt-sensitive sufferers.”

Olha Kravtsova, College of South Florida

“These outcomes additionally present a foundation for additional investigations of regional kidney metabolism. As well as, they spotlight lipid and inflammatory pathways as promising therapeutic targets within the therapy of hypertension.”